StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).

Schoffski, Patrick; Heinrich, Michael C; Trent, Jonathan C; Serrano, Cesar; Bauer, Sebastian; von Mehren, Margaret; Somaiah, Neeta; Reichardt, Peter; Demetri, George D; Lydon, Nick; Verweij, Jaap; Kadambi, Vivek; Christo, Jessica; Kim, Sean; Johnson, Debbie; Shao, James; George, Suzanne

Journal of Clinical Oncology

StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).

Author:

Schoffski, Patrick

Heinrich, Michael C ; Trent, Jonathan C ; Serrano, Cesar ; Bauer, Sebastian ; von Mehren, Margaret ; Somaiah, Neeta ; Reichardt, Peter ; Demetri, George D ; Lydon, Nick ; Verweij, Jaap ; Kadambi, Vivek ; Christo, Jessica ; Kim, Sean ; Johnson, Debbie ; Shao, James ; George, Suzanne

Keywords:

Science & Technology, Life Sciences & Biomedicine, Oncology, 1103 Clinical Sciences, 1112 Oncology and Carcinogenesis, Oncology & Carcinogenesis, 3211 Oncology and carcinogenesis

Journal of Clinical Oncology StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).

Author:

Keywords:

Journal of Clinical Oncology

StrateGIST 1: A first-in-human (FIH), phase 1 study of IDRX-42 in patients with metastatic gastrointestinal stromal tumors resistant to prior treatment with tyrosine kinase inhibitors (TKIs).